Picoplatin (** Generic name only (investigational drug - no approved brand names) **)

Chemotherapy

Description

Picoplatin is an investigational chemotherapy drug being studied for various solid tumors, including colorectal cancer. It is a platinum-based compound, similar to other chemotherapy drugs like cisplatin and carboplatin. The goal of the studies is to see if picoplatin can be given safely and effectively by mouth (oral capsule) compared to the standard way of giving it through a vein (intravenous injection). The studies are evaluating how the drug is absorbed, processed, and eliminated by the body when given orally versus intravenously. It is currently in early-phase clinical trials (Phase 1) to determine its safety and how it works in the body. It is not yet approved for use in treating colorectal cancer or any other cancer.

Mechanism of Action

Picoplatin is a platinum-based chemotherapy drug. Like other platinum drugs, it works by damaging the DNA inside cancer cells. This damage prevents the cancer cells from dividing and growing, ultimately leading to their death. The specific way picoplatin interacts with DNA is similar to other platinum compounds, but research is ongoing to fully understand its mechanism and potential advantages, especially when given orally.

Side Effects

As an investigational drug in Phase 1 trials The full range of side effects for picoplatin is still being evaluated. Side effects observed in early trials for platinum-based chemotherapy drugs often include nausea Vomiting Fatigue Low blood counts (affecting red blood cells White blood cells And platelets) Kidney problems Hearing loss And nerve damage (neuropathy). The specific side effects and their severity can vary depending on the dose How the drug is given (oral vs. IV) And the individual patient. More information about side effects will become available as clinical trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT00465725 med_phase_prefix1
Archived
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
United States